Integumen26 Jul 2019 12:15
Liz872 good post.
This is from the broker note on the RNS. The two new agreements, with clients whose identities currently remain
confidential for commercial reasons, are expected to provide Integumen with an increase in revenue per client as previous clients upgrade from Labskin products to the virtual service offering of LabskinAI. Integumen estimates that these two initial
deals could be worth over £100,000 in Q3 2019 alone and will likely increase for each additional product or ingredient tested throughout the remainder of the year.
The important point made is that
"Integumen estimates that these two initial deals could be worth over £100,000 in Q3 2019 alone and will likely increase for each additional product or ingredient tested throughout the remainder of the year."